Delivery Order SPE2DB22D2206-SPE2DB25FFQ53
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $49,926.80, is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 20, 2025 and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $68,649.37, is a Delivery Order contract for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of April 10, 2025 and is a Firm Fixed Price contract. There is no set-aside designation associated with this award. AmerisourceBergen...
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $74,890.20 firm fixed-price delivery order is for the supply of REVLIMID 10 MG CAPSULE 28S, a prescription medication. The award has an ultimate completion date of May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical, valued at...
- This is a $103,758.92 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of REVLIMID 5 MG CAPSULE 100S. The award has an ultimate completion date of July 14, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of REVLIMID 25 MG CAPSULE 21S. The contract has a firm fixed price ceiling value of $37,445.14 and an ultimate completion date of December 12, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for $49,926.80. The order is for REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of October 9, 2024 and is a firm fixed-price contract. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor. This order is likely part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, with a performance period through March 1, 2024 and a potential value of $27,599.94. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA with a potential value of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 10 MG CAPSULE 28S. The contract has a ceiling value of $212,188.94 and an ultimate completion date of September 24, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which serves as a primary vehicle for AmerisourceBergen to provide a comprehensive...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract, valued at $27,859.78, is for the delivery of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product, with a performance period through April 3, 2024. This delivery order is issued under an indefinite delivery contract (IDC) previously awarded to Amerisourcebergen Drug Corp...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 20 MG CAPSULE 100S. The award, valued at $89,155.06, has an ultimate completion date of October 8, 2024. AmerisourceBergen holds multiple Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for a comprehensive range of medical commodities. This...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FFQ53Delivery Order
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $89,155.06, is for the delivery of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 7, 2025. The contract was awarded on February 13, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $89.2k | 2/13/25 |